GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Days Sales Outstanding

Molecular Partners AG (XSWX:MOLN) Days Sales Outstanding : 92.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Days Sales Outstanding?

Molecular Partners AG's average Accounts Receivable for the three months ended in Dec. 2023 was CHF1.04 Mil. Molecular Partners AG's Revenue for the three months ended in Dec. 2023 was CHF1.03 Mil. Hence, Molecular Partners AG's Days Sales Outstanding for the three months ended in Dec. 2023 was 92.00.

The historical rank and industry rank for Molecular Partners AG's Days Sales Outstanding or its related term are showing as below:

XSWX:MOLN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.83   Med: 23.27   Max: 872.25
Current: 60.74

During the past 11 years, Molecular Partners AG's highest Days Sales Outstanding was 872.25. The lowest was 1.83. And the median was 23.27.

XSWX:MOLN's Days Sales Outstanding is ranked better than
59.73% of 894 companies
in the Biotechnology industry
Industry Median: 72.38 vs XSWX:MOLN: 60.74

Molecular Partners AG's Days Sales Outstanding increased from Dec. 2022 (38.14) to Dec. 2023 (92.00).


Molecular Partners AG Days Sales Outstanding Historical Data

The historical data trend for Molecular Partners AG's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Days Sales Outstanding Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 441.82 3.55 466.89 23.33 21.16

Molecular Partners AG Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.14 33.88 357.74 59.18 92.00

Competitive Comparison of Molecular Partners AG's Days Sales Outstanding

For the Biotechnology subindustry, Molecular Partners AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Days Sales Outstanding falls into.



Molecular Partners AG Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Molecular Partners AG's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (0.521 + 0.295) / 2 ) / 7.038*365
=0.408 / 7.038*365
=21.16

Molecular Partners AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (1.786 + 0.295) / 2 ) / 1.032*365 / 4
=1.0405 / 1.032*365 / 4
=92.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG  (XSWX:MOLN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Molecular Partners AG Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus